官方服务：
资源简介：
Complications and survival B/FEVAR.
应用场景：
创建时间：
2016-05-05
相关数据集
Aortic Stenosis Treatment Market Study by Transcatheter Aortic Valve Replacement, Surgical Aortic Valve Replacement, Balloon Valvuloplasty, Beta Blockers, and Cardiac Glycosides from 2024 to 2034
Worldwide revenue from aortic stenosis treatment solutions is expected to reach US$ 7.57 billion in 2024, as revealed in Fact.MR’s newly published market report. The global a
www.factmr.com2024-07-16 更新90
Mortality: TAVI versus medical therapy in surgically inoperable patients.
Mortality: TAVI versus medical therapy in surgically inoperable patients.
NIAID Data Ecosystem40
Supplementary Material for: Age-related outcomes of transcatheter aortic valve replacement in patients with pure severe aortic regurgitation
Abstract Background: Transcatheter aortic valve replacement (TAVR) has emerged as the recommended treatment for older patients with pure severe aortic regurgitation (PSAR). However, the efficacy of TA
Figshare2025-02-24 更新20
Primary venous patency of patients who underwent interposition graft reconstruction.
Primary venous patency of patients who underwent interposition graft reconstruction.
NIAID Data Ecosystem40
Characteristics of patients receiving transcatheter aortic valve replacement, surgical aortic valve replacement, and medical management for severe symptomatic aortic stenosis.
Characteristics of patients receiving transcatheter aortic valve replacement, surgical aortic valve replacement, and medical management for severe symptomatic aortic stenosis.
NIAID Data Ecosystem30
